- Home
- BFST vs TSHA Comparison
BFST vs TSHA Comparison
Compare BFST & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- TSHA
- Stock Information
- Founded
- BFST 2006
- TSHA 2019
- Country
- BFST United States
- TSHA United States
- Employees
- BFST N/A
- TSHA N/A
- Industry
- BFST Major Banks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- TSHA Health Care
- Exchange
- BFST Nasdaq
- TSHA Nasdaq
- Market Cap
- BFST 783.9M
- TSHA 728.4M
- IPO Year
- BFST 2018
- TSHA 2020
- Fundamental
- Price
- BFST $25.60
- TSHA $2.59
- Analyst Decision
- BFST Strong Buy
- TSHA Strong Buy
- Analyst Count
- BFST 3
- TSHA 6
- Target Price
- BFST $29.67
- TSHA $8.17
- AVG Volume (30 Days)
- BFST 117.2K
- TSHA 2.6M
- Earning Date
- BFST 07-28-2025
- TSHA 08-11-2025
- Dividend Yield
- BFST 2.14%
- TSHA N/A
- EPS Growth
- BFST N/A
- TSHA N/A
- EPS
- BFST 2.43
- TSHA N/A
- Revenue
- BFST $276,739,000.00
- TSHA $7,224,000.00
- Revenue This Year
- BFST $25.38
- TSHA N/A
- Revenue Next Year
- BFST $10.72
- TSHA N/A
- P/E Ratio
- BFST $10.79
- TSHA N/A
- Revenue Growth
- BFST 11.75
- TSHA N/A
- 52 Week Low
- BFST $20.07
- TSHA $1.05
- 52 Week High
- BFST $30.30
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- BFST 52.93
- TSHA 53.03
- Support Level
- BFST $25.32
- TSHA $2.34
- Resistance Level
- BFST $26.63
- TSHA $2.81
- Average True Range (ATR)
- BFST 0.62
- TSHA 0.15
- MACD
- BFST -0.07
- TSHA 0.01
- Stochastic Oscillator
- BFST 26.05
- TSHA 54.74
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.